Public Value Mapping of Equity in Emerging Nanomedicine

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Public values failure occurs when the market and the public sector fail to provide goods and services required to achieve the core values of society such as equity (Bozeman 2007). That public policy for emerging health technologies should address intrinsic societal values such as equity is not a novel concept. However, the ways that the public values discourse of stakeholders is structured is less clear and rarely studied through the lens of public interests. This is especially true in the health sciences discourse. Using the public value mapping (PVM) model I present a case study of the intrinsic value of equity in nanomedicine for cancer and the imperatives for translational research, an instrumental value to achieve equity. After reviewing and coding nearly 700 value statements from several hundred public documents, I find that that the discourse on values varies between documents that address basic research and documents that address the application of the knowledge produced in basic research, with some especially notable disconnections. This paper demonstrates the importance of further refinement of methods for testing the PVM framework if the societal goal is to improve consistency of the public value discussion by those involved in developing and applying new technologies. The paper also demonstrates the value of a PVM approach for complex science policy analysis, especially for emerging technologies like nanomedicine.

Original languageEnglish (US)
Pages (from-to)71-86
Number of pages16
JournalMinerva
Volume49
Issue number1
DOIs
StatePublished - Mar 1 2011

Fingerprint

equity
Values
basic research
discourse
science policy
health science
public interest
coding
new technology
public sector
cancer
public policy
stakeholder
market
health

Keywords

  • Health care disparities
  • Nanotechnology
  • Public values
  • Science and society

ASJC Scopus subject areas

  • Education
  • Social Sciences (miscellaneous)
  • Social Sciences(all)

Cite this

Public Value Mapping of Equity in Emerging Nanomedicine. / Slade, Catherine P.

In: Minerva, Vol. 49, No. 1, 01.03.2011, p. 71-86.

Research output: Contribution to journalReview article

@article{8707291a2a354a67b075acf2e3db9ea3,
title = "Public Value Mapping of Equity in Emerging Nanomedicine",
abstract = "Public values failure occurs when the market and the public sector fail to provide goods and services required to achieve the core values of society such as equity (Bozeman 2007). That public policy for emerging health technologies should address intrinsic societal values such as equity is not a novel concept. However, the ways that the public values discourse of stakeholders is structured is less clear and rarely studied through the lens of public interests. This is especially true in the health sciences discourse. Using the public value mapping (PVM) model I present a case study of the intrinsic value of equity in nanomedicine for cancer and the imperatives for translational research, an instrumental value to achieve equity. After reviewing and coding nearly 700 value statements from several hundred public documents, I find that that the discourse on values varies between documents that address basic research and documents that address the application of the knowledge produced in basic research, with some especially notable disconnections. This paper demonstrates the importance of further refinement of methods for testing the PVM framework if the societal goal is to improve consistency of the public value discussion by those involved in developing and applying new technologies. The paper also demonstrates the value of a PVM approach for complex science policy analysis, especially for emerging technologies like nanomedicine.",
keywords = "Health care disparities, Nanotechnology, Public values, Science and society",
author = "Slade, {Catherine P.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1007/s11024-011-9163-5",
language = "English (US)",
volume = "49",
pages = "71--86",
journal = "Minerva",
issn = "0026-4695",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Public Value Mapping of Equity in Emerging Nanomedicine

AU - Slade, Catherine P.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Public values failure occurs when the market and the public sector fail to provide goods and services required to achieve the core values of society such as equity (Bozeman 2007). That public policy for emerging health technologies should address intrinsic societal values such as equity is not a novel concept. However, the ways that the public values discourse of stakeholders is structured is less clear and rarely studied through the lens of public interests. This is especially true in the health sciences discourse. Using the public value mapping (PVM) model I present a case study of the intrinsic value of equity in nanomedicine for cancer and the imperatives for translational research, an instrumental value to achieve equity. After reviewing and coding nearly 700 value statements from several hundred public documents, I find that that the discourse on values varies between documents that address basic research and documents that address the application of the knowledge produced in basic research, with some especially notable disconnections. This paper demonstrates the importance of further refinement of methods for testing the PVM framework if the societal goal is to improve consistency of the public value discussion by those involved in developing and applying new technologies. The paper also demonstrates the value of a PVM approach for complex science policy analysis, especially for emerging technologies like nanomedicine.

AB - Public values failure occurs when the market and the public sector fail to provide goods and services required to achieve the core values of society such as equity (Bozeman 2007). That public policy for emerging health technologies should address intrinsic societal values such as equity is not a novel concept. However, the ways that the public values discourse of stakeholders is structured is less clear and rarely studied through the lens of public interests. This is especially true in the health sciences discourse. Using the public value mapping (PVM) model I present a case study of the intrinsic value of equity in nanomedicine for cancer and the imperatives for translational research, an instrumental value to achieve equity. After reviewing and coding nearly 700 value statements from several hundred public documents, I find that that the discourse on values varies between documents that address basic research and documents that address the application of the knowledge produced in basic research, with some especially notable disconnections. This paper demonstrates the importance of further refinement of methods for testing the PVM framework if the societal goal is to improve consistency of the public value discussion by those involved in developing and applying new technologies. The paper also demonstrates the value of a PVM approach for complex science policy analysis, especially for emerging technologies like nanomedicine.

KW - Health care disparities

KW - Nanotechnology

KW - Public values

KW - Science and society

UR - http://www.scopus.com/inward/record.url?scp=79953061759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953061759&partnerID=8YFLogxK

U2 - 10.1007/s11024-011-9163-5

DO - 10.1007/s11024-011-9163-5

M3 - Review article

AN - SCOPUS:79953061759

VL - 49

SP - 71

EP - 86

JO - Minerva

JF - Minerva

SN - 0026-4695

IS - 1

ER -